Press Release

Back to Press Release List

SITC Poster Presentation: “Development of KSQ-001, an Engineered TIL (eTIL™) Therapy for Solid Tumors through CRISPR/Cas9-mediated Inactivation of SOCS1”

Click image to enlarge.

Click to download PDF file.

© 2022 KSQ Therapeutics, Inc. All rights reserved.